Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.
Direct-to-consumer advertising can be a controversial topic in the pharma industry. While the US isn’t the only other country ...
Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.
The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...